Do not Disregard the Standardization of Vaccine Research
The Food and Drug Monitoring Agency (BPOM) confirmed that research for the Nusantara vaccine cannot continue onto its second phase as many aspects need to be corrected according to scientific principles.
BANDUNG, KOMPAS – Controversy regarding the development of the Nusantara vaccine must be resolved immediately so as not to hamper COVID-19 vaccine needs in the country. For optimal results, research standardization should not be ignored.
Food and Drug Monitoring Agency (BPOM) head Penny K. Lukito emphasized, while reviewing the development of the Merah Putih vaccine at Bio Farma, Bandung, West Java, Friday (16/4/2021), that vaccine development must adhere to the existing standards as it concerns human safety.